ArticleScientific reports2025
Accurate bladder cancer diagnosis using ensemble deep leaning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Matrix Metalloproteinases and Pro-Inflammatory Cytokines in Bladder Cancer: Diagnostic and Prognostic Perspectives: Narrative Review.International journal of molecular sciences · 2026Review
- Enhanced CT-based deep learning radiomics for bladder cancer prognosis.Military Medical Research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are an estimated 1.3 million cases of cancer globally each year, making it one of the most serious types of urinary tract cancer. The methods used today for diagnosing and monitoring bladder cancer are intrusive, costly, and time-consuming. In clinical practice, invasive biopsy followed by histological examination continues to be the gold standard for diagnosis. Bladder cancer biomarkers have been used in expensive diagnostic tests created recently, however their reliability is limited by their high rates of false positives and false negatives. The potential and use of artificial intelligence in urological diseases have been the subject of several research, as interest in artificial intelligence in medicine has grown recently. In this paper, a new bladder cancer model called Ensemble Deep Learning (EDL) will be provided to accurately diagnose patients. Outlier rejection is used to filter data using the interquartile range (IQR) then the image diagnosis. The proposed EDL consists of three deep learning algorithms, which are; Convolutional Neural Network (CNN), Generative Adversarial Network (GAN), and a new deep learning method called Explainable Deep Learning (XDL) that depends on Guided Gradient Weighted Class Activation Map (Guided Grad-CAM). In fact, Guided Grad-CAM enables doctor to understand the diagnose. A new voting mechanism will be used to integrate the results of all three methods to produce the final result to accurately diagnose bladder cancer cases. In fact, the used voting method depends on using majority voting based on two different scenarios according to the results of CNN, GAN, and XDL. If these three methods give the same class category, then the final diagnosis will be this class category. On the other hand, if the three methods give different class category, then the final result will be followed by the accuracy of each class. The proposed EDL model was tested after several trials. The results have proved that EDL model is more efficient and more accurate to diagnose bladder cancer disease. It introduced the highest accuracy results and the lowest error results as well as execution time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.